Ralpancizumab

Ralpancizumab
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	neural apoptosis-regulated proteinase 1
Identifiers
CAS Number	1407495-04-8
ATC code	None
ChemSpider	none
Chemical data
Formula	C₆₄₂₂H₉₉₂₂N₁₇₃₀O₂₀₁₂S₅₄
Molar mass	145.3 kg/mol

Ralpancizumab^[1] is a monoclonal antibody designed for the treatment of dyslipidemia.^[2]

This drug was developed by Pfizer.

References

↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information 27 (4).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone ("-os-", "-s(o)-")

Human ("-osu-")	Denosumab

Humanized ("-sozu-")	Blosozumab Romosozumab

Musculoskeletal ("-mul-")

Human ("-mulu-")	Stamulumab^†

Circulatory ("-c(i[r])-")

Human ("-ciru-")	Alirocumab Ascrinvacumab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab Vesencumab

Mouse ("-ciro-")	Biciromab^‡ Imciromab^‡

Chimeric ("-cixi-")	Abciximab Volociximab

Humanized ("-cizu-")	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Caplacizumab Demcizumab Etaracizumab Idarucizumab Ralpancizumab Tadocizumab

Neurologic ("-ne(u)(r)-")

Human ("-neru-")	Aducanumab Atinumab Fasinumab Fulranumab Gantenerumab Opicinumab

Humanized ("-nezu-"/"-neuzu-")	Bapineuzumab^† Crenezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab

Angiogenesis inhibitor ("-anibi-")

Humanized ("-anibizu-")	Ranibizumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.